Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978581 | 0.98 | BACE1 (0.50) | BACE1HSD11B2HSD11B1ALDH1A1L3MBTL1 | |
| SCHEMBL1025471 | 0.97 | BACE1 (0.48) | BACE1HSD11B2HSD11B1MAP4K4PDE5A | |
| SCHEMBL976986 | 0.95 | BACE1 (0.46) | BACE1HSD11B2HSD11B1ALDH1A1L3MBTL1 | |
| SCHEMBL9607812 | 0.84 | HSD11B1 (0.41) | BACE1HSD11B2HSD11B1ALDH1A1L3MBTL1 | |
| SCHEMBL9607809 | 0.84 | CSNK1A1 (0.43) | HSD11B2HSD11B1ALDH1A1L3MBTL1 | |
| SCHEMBL9607820 | 0.83 | ALDH1A1 (0.43) | BACE1HSD11B2HSD11B1ALDH1A1L3MBTL1 | |
| SCHEMBL9607808 | 0.83 | CSNK1A1 (0.42) | HSD11B2HSD11B1ALDH1A1L3MBTL1 | |
| SCHEMBL9607813 | 0.81 | BACE1 (0.54) | BACE1ALDH1A1L3MBTL1SLC6A4SLC6A3 | |
| SCHEMBL9607811 | 0.80 | BACE1 (0.54) | BACE1ALDH1A1L3MBTL1SLC6A4SLC6A3 | |
| SCHEMBL9607818 | 0.79 | CSNK1A1 (0.44) | HSD11B2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229371-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2015-12-23 | — | — | EP | claimed |
| EP-3002280-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2023-05-24 | — | — | EP | disclosed |
| US-9862691-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2018-01-09 | — | — | US | disclosed |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2016-10-27 | — | — | US | disclosed |
| US-9422253-B2 | Cyclic triazo and diazo sodium channel blockers | UNIVERSITY OF GREENWICH (GB) | 2016-08-23 | — | — | US | disclosed |
| EP-3002280-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2016-04-06 | — | — | EP | disclosed |
| EP-2229371-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-20140155403-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2014-06-05 | — | — | US | disclosed |
| CN-101918378-B | Cyclic azide and sodium diazoxide channel blockers | UNIV GREENWICH | 2013-12-04 | — | — | CN | disclosed |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2011-01-13 | — | — | US | disclosed |
| CN-101918378-A | Cyclic azide and sodium diazoxide channel blockers | UNIV GREENWICH | 2010-12-15 | — | — | CN | disclosed |
| EP-2229371-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | University of Greenwich (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009090431-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIVERSITY OF GREENWICH (GB) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155403-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | SCN1A, SCN1B, SCN3A | BACE1 2641/4885HSD11B2 853/4885HSD11B1 1001/4885 |
| US-20110009413-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | CACNA1E, SCN2B, SCN3A | BACE1 203/4885HSD11B2 3861/4885HSD11B1 3860/4885 |
| US-20160311784-A1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | SCN1A, SCN1B, SCN3A | BACE1 3078/4885HSD11B2 1000/4885HSD11B1 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.